Posted on 1 Comment

MindMed (MNMD) Stock Review #2 – September 2021. Solving the opioid crisis, anxiety, and ADHD!



Check out this revolutionary company that will be, if not the leader, one of the top businesses to tackle improvements to mental health. A once in a lifetime …

source

1 thought on “MindMed (MNMD) Stock Review #2 – September 2021. Solving the opioid crisis, anxiety, and ADHD!

  1. Great summary of MindMed's achievements and where MNMD is headed. I bought a lot of shares early on and I'm holding until FDA approval. Eight to 10 years? I'm not selling.

Leave a Reply

Your email address will not be published. Required fields are marked *